<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: De novo <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> is not uncommon after liver transplantation (OLT) </plain></SENT>
<SENT sid="1" pm="."><plain>We have compared the incidence of novo <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> following OLT with those among the general Korean population </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Between January 1998 and December 2008, 1952 adult OLT were performed, including 1714 living donor and 238 deceased donor grafts whose medical records were retrospectively reviewed </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Among the 1952 patients, 44 (2.3%) showed de novo <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> after a mean posttransplant period of 41 months </plain></SENT>
<SENT sid="4" pm="."><plain>Among the 14 types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> the most frequent was <z:hpo ids='HP_0012126'>stomach cancer</z:hpo> (n = 11; 25.0%), <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (n = 9; 20.5%), <z:hpo ids='HP_0003002'>breast cancer</z:hpo> (n = 4; 9.1%), and <z:e sem="disease" ids="C0007115" disease_type="Neoplastic Process" abbrv="">thyroid cancer</z:e> (n = 3; 6.8%) </plain></SENT>
<SENT sid="5" pm="."><plain>These patients underwent aggressive treatment, including surgery, chemotherapy, and radiotherapy, except for one patient with an aggressive primary <z:hpo ids='HP_0002896'>liver cancer</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Over a mean follow-up of 45 months after diagnosis of de novo <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, 13 patients (29.5%) died; the overall 3-year patient survival rate was 67.5% </plain></SENT>
<SENT sid="7" pm="."><plain>The relative risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> following OLT was 7.7-fold higher in men and 7.3-fold higher in women than the Korean general population </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: OLT recipients must be checked periodically for de novo <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> throughout their lives, especially for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> common in the general population </plain></SENT>
</text></document>